Browsing by Author "Martínez, María Teresa"

Sort by: Order: Results:

  • MicroRNA-33b suppresses epithelial-mesenchymal transition repressing the MYC-EZH2 pathway in HER2+ breast carcinoma
    Pattanayak, Birlipta; Garrido Cano, Iris; Adam-Artigues, Anna; Tormo, Eduardo; Pineda, Begoña; Cabello, Paula; Alonso, Elisa; Bermejo, Begoña; Hernando, Cristina; Martínez, María Teresa; Rovira, Ana; Albanell Mestres, Joan; Rojo, Federico; Burgués, Octavio; Cejalvo, Juan M.; Lluch, Ana; Eroles, Pilar (Frontiers, 2020)
    Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) ...
  • miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer
    Cabello, Paula; Torres-Ruiz, Sandra; Adam-Artigues, Anna; Forés-Martos, Jaume; Martínez, María Teresa; Hernando, Cristina; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell Mestres, Joan; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel; Eroles, Pilar (MDPI, 2023)
    Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication ...
  • NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
    Santana-Hernández, Sara; Suárez Olmos, Jesús; Servitja Tormo, Sonia; Berenguer-Molins, Pau; Costa García, Marcel, 1989-; Comerma Blesa, Laura, 1983-; Rea, Anna; Perera Bel, Júlia; Menendez Romero, Silvia; Arpí Llucià, Oriol; Bermejo, Begoña; Martínez, María Teresa; Cejalvo, Juan Miguel; Comino-Méndez, Iñaki; Pascual, Javier; Alba, Emilio; López-Botet, M. (Miguel); Rojo, Federico; Rovira, Ana; Albanell Mestres, Joan; Muntasell i Castellví, Aura, 1972- (BioMed Central, 2024)
    Background: The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural ...
  • Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
    Tibau, Ariadna; Martínez, María Teresa; Ramos, Manuel; Cruz-Merino, Luis; Santaballa, Ana; O'Connor, Miriam; Martínez-Jáñez, Noelia; Moreno, Fernando; Fernández, Isaura; Virizuela, Juan Antonio; Alarcón, Jesús; Haba Rodríguez, Juan de la; Sánchez-Rovira, Pedro; Albacar, Cinta Rosa; Bueno Muiño, Carolia; Kelly, Catherine; Casas Sanahuja, Maribel; Bezares, Susana; Rosell, Libertad; Albanell Mestres, Joan (SAGE Publications, 2023)
    Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2- advanced breast cancer (ABC). ...
  • Role of SALL4 in HER2+ breast cancer progression: Regulating PI3K/AKT pathway
    Pattanayak, Birlipta; Lameirinhas, Ana; Torres-Ruiz, Sandra; Burgués, Octavio; Rovira, Ana; Martínez, María Teresa; Tapia, Marta; Zazo, Sandra; Albanell Mestres, Joan; Rojo, Federico; Bermejo, Begoña; Eroles, Pilar (MDPI, 2022)
    Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms of transcription factors may help to make treatment regimens more ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking